AAPL 192.4902 0.7591% MSFT 429.38 0.9498% GOOG 179.04 0.325% GOOGL 177.45 0.2996% AMZN 182.02 -0.8282% NVDA 947.4001 -0.0422% META 464.53 -0.9193% TSLA 186.0554 6.3478% TSM 153.42 -0.0847% LLY 803.85 2.6392% V 276.17 -0.8509% AVGO 1399.41 -1.0339% JPM 198.68 1.585% UNH 522.2967 0.9796% NVO 134.5401 1.2265% WMT 64.9 1.1218% LVMUY 166.815 -1.2052% XOM 118.03 -0.5393% LVMHF 846.034 0.1224% MA 457.885 -0.3862%

Eiger Biopharmaceuticals Inc

Healthcare US EIGR


Last update at 2024-05-08T13:30:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -96.75300M -33.85300M -65.05100M -70.25200M -52.39100M
Minority interest - - - - -
Net income -96.77600M -33.91700M -68.63300M -73.64300M -52.39100M
Selling general administrative 29.11M 23.90M 20.56M 17.11M 13.96M
Selling and marketing expenses - - - - -
Gross profit 11.65M 11.40M - - 0.00000M
Reconciled depreciation 0.84M 0.80M 0.65M 0.49M 0.05M
Ebit -92.74000M -76.93900M -62.14900M -68.90400M -50.11600M
Ebitda -92.62100M -30.29400M -60.81200M -66.36000M -50.06200M
Depreciation and amortization 0.12M 46.65M 1.34M 2.54M 0.05M
Non operating income net other 0.12M 46.65M 0.69M 2.06M 0.98M
Operating income -92.74000M -76.93900M -62.14900M -68.90400M -51.04700M
Other operating expenses 106.22M 89.08M 62.15M 68.90M 51.05M
Interest expense 4.13M 3.56M 3.59M 3.41M 2.33M
Tax provision 0.02M 0.06M - - -
Interest income 1.08M 0.16M 0.70M 2.07M 1.00M
Net interest income -3.05000M -3.40100M -2.89000M -1.33300M -1.33200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.02M 0.06M 3.58M 3.39M 0.98M
Total revenue 13.48M 12.14M 0.00000M 0.00000M 0.00000M
Total operating expenses 104.39M 88.34M 62.15M 68.90M 51.05M
Cost of revenue 1.84M 0.74M - - 0.00000M
Total other income expense net -4.01300M 43.09M -2.90200M -1.34800M -0.01200M
Discontinued operations - - - - -
Net income from continuing ops -96.77600M -33.91700M -65.05100M -70.25200M -52.39100M
Net income applicable to common shares -96.77600M -33.91700M -65.05100M -70.25200M -52.39100M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 120.14M 126.40M 143.59M 105.14M 102.45M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 13.98M 9.36M 1.22M 5.39M 1.49M
Total liab 64.83M 54.00M 48.56M 48.66M 35.86M
Total stockholder equity 55.31M 72.40M 95.03M 56.48M 66.59M
Deferred long term liab - - - - -
Other current liab 15.65M 13.70M 11.40M 10.00M 4.19M
Common stock 0.04M 0.04M 0.03M 0.02M 0.02M
Capital stock 0.04M 0.04M 0.03M 0.02M 0.02M
Retained earnings -437.19300M -340.41700M -306.50000M -241.44900M -171.19700M
Other liab - - - - 0.21M
Good will - - - - -
Other assets 1.35M 4.51M 5.08M 2.51M 0.44M
Cash 25.80M 22.22M 28.86M 39.37M 61.26M
Cash and equivalents - - - - -
Total current liabilities 25.12M 29.90M 16.63M 16.95M 10.02M
Current deferred revenue - - - - -
Net debt 14.40M 10.32M 3.65M -7.12900M -35.64200M
Short term debt 0.49M 8.44M 0.58M 0.53M -
Short long term debt - 7.81M - - -
Short long term debt total 40.20M 32.54M 32.51M 32.24M 25.62M
Other stockholder equity 492.76M 412.93M 401.51M 297.86M 237.79M
Property plant equipment 0.70M 0.61M 0.71M 0.59M 0.17M
Total current assets 117.53M 103.36M 137.81M 100.38M 101.84M
Long term investments 0.00000M 17.26M - - -
Net tangible assets 55.31M 72.40M 95.03M 56.48M 66.59M
Short term investments 73.15M 66.59M 99.98M 55.62M 39.09M
Net receivables 1.75M 2.58M - - -
Long term debt 39.62M 23.99M 31.19M 30.39M 25.62M
Inventory 2.85M 2.61M 0.09M - -
Accounts payable 8.97M 7.76M 4.64M 6.41M 5.83M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.30000M -0.14900M -0.00800M 0.04M -0.02500M
Additional paid in capital - - - - -
Common stock total equity 0.04M 0.04M 0.03M 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity -437.19300M -340.41700M -306.50000M -241.44900M -171.19700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.35M 4.51M 3.90M 2.51M 0.44M
Deferred long term asset charges - - - - -
Non current assets total 2.60M 23.04M 5.79M 4.75M 0.60M
Capital lease obligations 0.57M 0.74M 1.32M 1.85M -
Long term debt total 39.62M 23.99M 31.19M 30.39M 25.62M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 9.97M 14.98M -44.52900M -15.99600M -28.94300M
Change to liabilities 3.11M 5.54M -0.40800M 6.19M 4.97M
Total cashflows from investing activities 9.63M 61.53M -44.78700M -16.47100M -29.08500M
Net borrowings 5.45M -0.17500M 6.56M 4.96M 9.94M
Total cash from financing activities 76.95M 3.17M 97.46M 58.20M 100.98M
Change to operating activities -0.13200M 0.42M -3.99800M -0.59300M 1.42M
Net income -96.77600M -33.91700M -65.05100M -70.25200M -52.39100M
Change in cash 3.58M -6.64300M -10.50900M -21.88900M 29.23M
Begin period cash flow 22.22M 28.86M 39.37M 61.26M 32.03M
End period cash flow 25.80M 22.22M 28.86M 39.37M 61.26M
Total cash from operating activities -83.01000M -71.34200M -63.18500M -63.61400M -42.67100M
Issuance of capital stock 71.40M 3.04M 96.78M 53.19M 90.64M
Depreciation 0.84M 0.80M 0.65M 0.49M 0.05M
Other cashflows from investing activities - 46.77M 46.49M -15.99600M -28.94300M
Dividends paid - - - -0.13000M -
Change to inventory -1.36700M -2.42400M -2.42400M -2.42400M -2.42400M
Change to account receivables 0.83M -2.57600M -2.57600M -2.57600M -2.57600M
Sale purchase of stock 0.16M 0.26M 0.19M 0.13M 0.43M
Other cashflows from financing activities 38.67M -0.13000M 0.50M 6.67M 9.91M
Change to netincome 10.52M 8.12M 6.19M 5.91M 5.01M
Capital expenditures 0.34M 48.73M 0.26M 0.47M 0.14M
Change receivables 0.83M -2.57600M - - -
Cash flows other operating -1.53900M -48.13500M -5.01100M -5.78500M -0.47600M
Exchange rate changes - - - - -
Cash and cash equivalents changes 3.58M -6.64300M -10.50900M -21.88900M 29.23M
Change in working capital 0.48M -1.34100M -5.89700M -0.00900M 4.07M
Stock based compensation 8.32M 7.90M 5.97M 5.68M 5.01M
Other non cash items 4.13M 0.71M 1.02M 0.95M 1.02M
Free cash flow -83.35000M -120.07400M -63.44300M -64.08900M -42.81300M


  • Previous Close -
  • Market Cap10.25M
  • Volume5723
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-83.35200M
  • Revenue TTM14.67M
  • Revenue Per Share TTM0.33
  • Gross Profit TTM 11.65M
  • Diluted EPS TTM-1.95

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Eiger Biopharmaceuticals Inc
2.60 -% 2.60 - - 0.70 0.87 0.81 -0.1465
Novo Nordisk A/S
1.63 1.23% 134.54 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
1.54 1.16% 134.67 41.06 31.25 2.08 33.11 2.11 4.70
Vertex Pharmaceuticals Inc
-6.66 1.49% 439.21 30.40 24.75 10.68 6.25 9.52 20.36
-0.16 0.17% 92.58 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News


Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Eiger Biopharmaceuticals Inc

2155 Park Boulevard, Palo Alto, CA, United States, 94306

Key Executives

Name Title Year Born
Mr. David A. Cory M.B.A., MBA, R.Ph, R.Ph. Bus. Founder, Pres, CEO & Director 1964
Dr. Jeffrey S. Glenn M.D., Ph.D. Scientific Founder & Independent Director 1963
Mr. Sriram Ryali M.B.A. Chief Financial Officer 1981
Mr. Eldon C. Mayer III, M.B.A. Exec. VP & Chief Commercial Officer 1961
Mr. Christopher A. Kurtz Chief Technical Officer 1967
Mr. Erik Atkisson Gen. Counsel, Corp. Sec. & Chief Compliance Officer 1972
Dr. Ingrid C. Choong Sr. VP of Clinical Devel. NA
Dr. Stephana E. Patton J.D., Ph.D. Consultant 1971
Mr. Rich Franco M.B.A. Sr. VP of Regulatory Affairs NA
Dr. Colin Hislop M.D. Sr. VP of Clinical & Devel. Operations 1958

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).